Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4), also known as HGK or NIK, is a serine/threonine kinase positioned upstream of the MAPK pathway. It plays a pivotal role in regulating cell motility, invasion, systemic inflammation, and cardiomyocyte death. Consequently, MAP4K4 has emerged as a high-value therapeutic target across oncology, cardiometabolic disorders, and ischemia-reperfusion injury.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MAP4K4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MAP4K4 Recombinant Protein (Kinase Domain / Full Length) High purity (>95%), Endotoxin Controlled, Sequence Verified, Theoretical MW confirmed. |
View MAP4K4 Products |
| Gene Delivery | MAP4K4 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and target overexpression. |
View MAP4K4 Products |
| Benchmark Ab | Anti-MAP4K4 Recombinant Antibody Recombinant positive control for Western Blot, ELISA, and Flow Cytometry. |
View MAP4K4 Products |
| Validator | MAP4K4 siRNA Set For target knockdown verification and phenotypic rescue assays. |
View MAP4K4 Products |
| Related Target A | TNF-alpha MAP4K4 is a critical mediator downstream of TNF-alpha, driving insulin resistance and inflammatory cytokine release. |
View TNF-alpha Products |
| Related Target B | MAP4K3 Key homolog for selectivity counter-screening to avoid off-target toxicities. |
View MAP4K3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase family selectivity (MAP4K subfamily off-targets) | High-purity MAP4K3, MAP4K5, and related STE20-like kinase proteins available for parallel profiling. |
| Cell-based functional validation | High-titer Lentiviral particles and sequence-verified siRNA sets for robust knockdown/overexpression. |
| Lack of Controls | Clinical Benchmark Recombinant Antibodies included as assay standards. |
| False Positives | Validated siRNA included for specificity and phenotypic rescue checks. |
Live MAP4K4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MAP4K4 therapeutics is intensifying, with major players shifting focus from traditional multi-kinase inhibitors to highly selective small molecules and targeted protein degradation (PROTACs). As first-generation systemic inhibitors reach the clinic, the next wave of R&D is targeting tissue-specific delivery and isoform-selective inhibition to treat cardiac injury and metastatic solid tumors without systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Pfizer, Novartis, Genentech | Cardiomyocyte Protection, Heart Failure, Ischemia-Reperfusion | Kinase Selectivity Assay (Need high-purity Kinase domain WT & Homologs) |
| PROTAC / Degraders | Academic / Biotech Startups | Solid Tumors (Glioblastoma, Pancreatic Cancer) | Target Engagement & Binding Kinetics (Need high-purity WT protein for SPR) |
| RNAi / siRNA | Alnylam, Academic Groups | Metastatic Cancers, Cachexia | In vitro Knockdown Validation (Need validated siRNA / qPCR controls) |